United Therapeutics Corp. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,233 shares of the stock in a transaction dated Friday, November 25th. The shares were sold at an average price of $132.81, for a total transaction of $163,754.73. Following the transaction, the chief executive officer now directly owns 1,373 shares of the company’s stock, valued at approximately $182,348.13. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Corp. (NASDAQ:UTHR) opened at 125.61 on Thursday. The stock has a market capitalization of $5.33 billion, a price-to-earnings ratio of 8.50 and a beta of 1.39. The stock’s 50 day moving average is $122.42 and its 200-day moving average is $118.39. United Therapeutics Corp. has a 12 month low of $97.52 and a 12 month high of $164.04.

United Therapeutics Corp. (NASDAQ:UTHR) last announced its quarterly earnings data on Thursday, October 27th. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.38 by $0.98. United Therapeutics Corp. had a net margin of 44.40% and a return on equity of 41.78%. The company earned $408.20 million during the quarter, compared to analysts’ expectations of $400.58 million. During the same quarter in the prior year, the company earned $3.55 EPS. United Therapeutics Corp.’s revenue was up 5.7% compared to the same quarter last year. On average, equities research analysts expect that United Therapeutics Corp. will post $16.29 earnings per share for the current year.

Insider Buying and Selling by Quarter for United Therapeutics Corp. (NASDAQ:UTHR)

COPYRIGHT VIOLATION NOTICE: “Martine A. Rothblatt Sells 1,233 Shares of United Therapeutics Corp. (UTHR) Stock” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and reposted in violation of international copyright and trademark laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2016/12/01/martine-a-rothblatt-sells-1233-shares-of-united-therapeutics-corp-uthr-stock.html.

A number of hedge funds have recently made changes to their positions in UTHR. Fisher Asset Management LLC boosted its stake in shares of United Therapeutics Corp. by 1.0% in the third quarter. Fisher Asset Management LLC now owns 3,124 shares of the biotechnology company’s stock valued at $369,000 after buying an additional 32 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in shares of United Therapeutics Corp. by 0.6% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,373 shares of the biotechnology company’s stock valued at $753,000 after buying an additional 35 shares in the last quarter. Ifrah Financial Services Inc. boosted its stake in shares of United Therapeutics Corp. by 0.8% in the second quarter. Ifrah Financial Services Inc. now owns 4,642 shares of the biotechnology company’s stock valued at $492,000 after buying an additional 39 shares in the last quarter. Sumitomo Mitsui Asset Management Company LTD boosted its stake in shares of United Therapeutics Corp. by 1.6% in the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 3,194 shares of the biotechnology company’s stock valued at $338,000 after buying an additional 50 shares in the last quarter. Finally, First Citizens Bank & Trust Co. boosted its stake in shares of United Therapeutics Corp. by 1.4% in the third quarter. First Citizens Bank & Trust Co. now owns 3,684 shares of the biotechnology company’s stock valued at $435,000 after buying an additional 50 shares in the last quarter.

A number of research analysts recently commented on the stock. Wedbush reaffirmed an “outperform” rating and issued a $229.00 price target on shares of United Therapeutics Corp. in a report on Friday, November 4th. Cowen and Company reaffirmed a “buy” rating and issued a $144.00 price target on shares of United Therapeutics Corp. in a report on Friday, September 23rd. Zacks Investment Research downgraded shares of United Therapeutics Corp. from a “buy” rating to a “hold” rating in a report on Thursday, October 20th. Barclays PLC downgraded shares of United Therapeutics Corp. from an “equal weight” rating to an “underweight” rating and lowered their price target for the company from $115.00 to $100.00 in a report on Tuesday. Finally, Ladenburg Thalmann raised shares of United Therapeutics Corp. from a “neutral” rating to a “buy” rating and increased their price target for the company from $128.00 to $138.00 in a report on Friday, October 28th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $133.42.

United Therapeutics Corp. Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

5 Day Chart for NASDAQ:UTHR

Receive News & Stock Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related stocks with our FREE daily email newsletter.